文献速递心律失常心力衰竭与心肌病

LMNA突变携带者长期心律失常与非心律失常结局

Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers.
PubMed 文献 · J Am Coll Cardiol · 2016-01-01

该回顾性研究纳入122例LMNA突变携带者,中位随访7年,发现表型进展率高:房室传导阻滞从46%升至57%,房性心律失常从39%升至63%,室性心律失常从16%升至34%,左室收缩功能障碍从44%升至57%。男性、非错义突变和基线左室收缩功能障碍与室性心律失常相关,而左室收缩功能障碍与终末期心衰或死亡相关。初始心脏表型不能预测不良事件。

要点

  • LMNA突变携带者长期随访中表型进展和不良事件发生率高。
  • 男性、非错义突变和基线左室收缩功能障碍与室性心律失常相关。
  • 初始心脏表型不能预测室性心律失常或终末期心衰或死亡。

核心结论

  • LMNA相关心脏病在长期随访中与高比例的临床表型进展及不良心律失常和非心律失常事件相关。
  • 初始心脏表型不能预测室性心律失常或终末期心衰或死亡。
  • 遗传诊断及后续随访(包括预防猝死和管理心衰的提前规划)是必要的。

研究设计与样本

  • 回顾性研究,纳入122例连续的LMNA突变携带者,来自5个转诊中心,从首次临床接触起中位随访7年。
  • 评估房室传导阻滞、房性心律失常、持续性室性心律失常、左室收缩功能障碍(左室射血分数≤50%)和终末期心衰的发生率,并确定室性心律失常和终末期心衰或死亡的预测因素。

主要发现

  • 从初始评估到中位随访,临床表现的患病率广泛增加:房室传导阻滞从46%升至57%,房性心律失常从39%升至63%,室性心律失常从16%升至34%,左室收缩功能障碍从44%升至57%。
  • 59%的患者因新发左室收缩功能障碍或房室传导阻滞植入了植入式心律转复除颤器。
  • 19%的患者发生终末期心衰,13%死亡。
  • 在就诊时无左室收缩功能障碍的患者中,24%出现新发左室收缩功能障碍,7%发生终末期心衰。
  • 男性(p=0.01)、非错义突变(p=0.03)和初始评估时左室收缩功能障碍(p=0.004)与室性心律失常发生相关,而左室收缩功能障碍与终末期心衰或死亡相关(p<0.001)。

临床怎么用

  • 对LMNA突变携带者应进行遗传诊断和长期随访,包括提前规划预防猝死的治疗和管理心衰。
  • 关注男性、非错义突变和基线左室收缩功能障碍的患者,因其室性心律失常风险较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutations in LMNA are variably expressed and may cause cardiomyopathy, atrioventricular block (AVB), or atrial arrhythmias (AAs) and ventricular arrhythmias (VA). Detailed natural history studies of LMNA-associated arrhythmic and nonarrhythmic outcomes are limited, and the prognostic significance of the index cardiac phenotype remains uncertain. OBJECTIVES: This study sought to describe the arrhythmic and nonarrhythmic outcomes of LMNA mutation carriers and to assess the prognostic significance of the index cardiac phenotype. METHODS: The incidence of AVB, AA, sustained VA, left ventricular systolic dysfunction (LVD) (= left ventricular ejection fraction ≤50%), and end-stage heart failure (HF) was retrospectively determined in 122 consecutive LMNA mutation carriers followed at 5 referral centers for a median of 7 years from first clinical contact. Predictors of VA and end-stage HF or death were determined. RESULTS: The prevalence of clinical manifestations increased broadly from index evaluation to median follow-up: AVB, 46% to 57%; AA, 39% to 63%; VA, 16% to 34%; and LVD, 44% to 57%. Implantable cardioverter-defibrillators were placed in 59% of patients for new LVD or AVB. End-stage HF developed in 19% of patients, and 13% died. In patients without LVD at presentation, 24% developed new LVD, and 7% developed end-stage HF. Male sex (p = 0.01), nonmissense mutations (p = 0.03), and LVD at index evaluation (p = 0.004) were associated with development of VA, whereas LVD was associated with end-stage HF or death (p < 0.001). Mode of presentation (with isolated or combination of clinical features) did not predict sustained VA or end-stage HF or death. CONCLUSIONS: LMNA-related heart disease was associated with a high incidence of phenotypic progression and adverse arrhythmic and nonarrhythmic events over long-term follow-up. The index cardiac phenotype did not predict adverse events. Genetic diagnosis and subsequent follow-up, including anticipatory planning for therapies to prevent sudden death and manage HF, is warranted.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. J Am Coll Cardiol. 2016. PMID: 27884249. doi:10.1016/j.jacc.2016.08.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。